HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Dare Bioscience (NASDAQ:DARE) and maintained a $7 price target.
June 06, 2023 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dare Bioscience (NASDAQ:DARE) receives a reiterated Buy rating and a maintained $7 price target from HC Wainwright & Co. analyst Douglas Tsao.
The reiterated Buy rating and maintained $7 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Dare Bioscience. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100